Desjardins A, Gromeier M, Herndon II JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 2018;379:12 de juliol. [Ref.ID 102734]

Feuerstein A. Juno Therapeutics could shake up CAR-T market with strong lymphoma data. STAT 2017:1. [Ref.ID 102111]

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon Ch, Harden M, Lennon N, Gabriel S, Rodig S, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017;547:217-21. [Ref.ID 101662]

Pfeffer MA, McMurray JJV. Lessons in uncertainty and humility — Clinical trials involving hypertension. N Engl J Med 2016;375:1756-66. [Ref.ID 100966]

Anónimo. Alzheimer’s researchers optimistic after positive results from phase I clinical trial of aducanumab. DIA Daily 2016:3. [Ref.ID 100832]

Dal-Ré R. Desarrollo clínico de nuevos medicamentos. Seguridad de los ensayos clínicos en voluntarios sanos. Med Clin (Barc) 2016;147:154-6. [Ref.ID 100648]

Anónimo. FDA grants Biogen fast-track designation for Alzheimer’s drug. Kaiser Health News 2016:1. [Ref.ID 100625]

Anónimo. Aducanumab shows encouraging results as Alzheimer’s treatment in early clinical trial. DIA Daily 2016:3. [Ref.ID 100617]

Moore N. Lessons from the fatal French study BIA-10-2474. BMJ 2016;353:i2727. [Ref.ID 100424]

Casassus B. New report on drug trial disaster in France. Lancet 2016;387:2187. [Ref.ID 100334]

Casassus B. France releases interim report on drug trial disaster. Lancet 2016;387:634-5. [Ref.ID 100049]

Casassus B. France investigates drug trial disaster. Lancet 2016;387:326. [Ref.ID 99978]

Anónimo. One dead, five hospitalized in French clinical trial. DIA Daily 2016:19 de enero. [Ref.ID 99970]

Glund S, Stangier J, Schmohl M, Gansser D, Norris S, Van Ryn J, Lang B, Ramael S, Moschetti V, Gruenenfelder F, Reilly P, Kreuzer J. Articles Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015;386:680-90. [Ref.ID 99494]

Kimmelman J. The secret realm of phase I trials in healthy volunteers. BMJ 2015;350:h3444. [Ref.ID 99219]

Emanuel EJ, Bedarina G, Macci K, Gabler NB, Rid A, Wendler D. Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studies. BMJ 2015;350:h3271. [Ref.ID 99218]

Dyer O. Experimental drug that injured UK volunteers resumes in human trials. BMJ 2015;350:h1831. [Ref.ID 98941]

Anónimo. Experimental Alzheimer’s treatment slows cognitive decline in early trial. DIA Daily 2015:23 de marzo. [Ref.ID 98868]

Anónimo. Joint pain pauses Merck Ebola vaccine’s phase I. DIA Daily 2014:12 de diciembre. [Ref.ID 98386]

Koenekoop RK, Sui R, Sallum J, van der Born LI, Ajlan R, Khan A, den Hollander AI, Cremers FPM, Mendola JD, Bittner AK, Dagnelie G, Schuchard RA, Saperstein DA. Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial. Lancet 2014;384:1513-20. [Ref.ID 98252]